查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1701375

糖尿病足溃疡生技药品市场规模、份额、趋势分析报告：按产品、适应症、最终用途、地区和细分市场预测，2025 年至 2030 年

Diabetic Foot Ulcer Biologics Market Size, Share & Trends Analysis Report By Product, By Indication, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 140 Pages | 商品交期: 2-10个工作天内

价格

糖尿病足溃疡生技药品市场的成长与趋势

根据 Grand View Research, Inc. 的最新报告，全球糖尿病足溃疡生技药品市场规模预计到 2030 年将达到 31.1 亿美元，2025 年至 2030 年的复合年增长率为 7.9%。

这种增长是由市场参与企业之间日益激烈的竞争、研究活动的活性化以及人口老化导致的临床测试和研究的增加所推动的。此外，工业公司扩大影响力的重点也有望在未来几年推动市场成长。

例如，美国国家医学图书馆于 2022 年 8 月发表的一项研究报告称，糖尿病足溃疡 (DFU) 的风险会随着年龄的增长而增加。这种相关性与糖尿病病程较长、高血糖的累积效应以及微血管和大血管併发症的盛行率较高密切相关。因此，老年人口的增加预计会导致糖尿病足溃疡的增加。根据世界卫生组织2024年10月发布的资料，预计未来几年老年人口数将大幅增加。以下是世界卫生组织的预测：

  • 到2030年，全球每六人中就有一人年龄超过60岁，从2020年的10亿增加到14亿。
  • 到2050年，全球60岁以上人口预计将翻一番，达到21亿人。
  • 预计2020年至2050年间，80岁以上人口将增加两倍，达4.26亿。

此外，预计在预测期内，多家公司将开始开发糖尿病足溃疡的创新治疗方法，临床试验的数量也将不断增加，这也将推动市场的发展。各行业参与者都积极参与临床试验，以带来新型生技药品。例如，2025年1月，临床阶段再生医学公司RION宣布完成其精製外泌体製剂（PEP）治疗糖尿病足溃疡（DFU）的2期临床试验的患者招募。这项前瞻性、多中心、开放标籤研究旨在招募美国 59 名患者，并评估与标准伤口护理同时应用局部PEP 的安全性和有效性。 PEP 是一种源自人类血小板的专有冻干粉，其中含有稳定的再生外泌体。外泌体旨在透过促进细胞增殖和减少发炎来增强人体的自然癒合过程，同时保护脆弱的组织，这是成功创伤治疗的重要组成部分。

糖尿病足溃疡生技药品市场报告重点

  • 根据产品，2024 年糖尿病足溃疡生技药品市场在全球市场中以皮肤替代品部分为主。另一方面，组织工程产品领域预计未来几年将实现最快成长。
  • 按适应症划分，神经缺血性溃疡领域在 2024 年占据市场最大收益占有率，约 53.17%。相较之下，缺血性糖尿病足溃疡领域预计在预测期内以最快的复合年增长率成长。
  • 根据最终用途，医院部门占据市场主导地位，2024 年的收益占有率为 51.52%。然而，门诊手术中心部门预计在预测期内将以最快的速度成长。

目录

第一章调查方法与范围

第二章执行摘要

3. 糖尿病足溃疡生技药品市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
    • 市场问题分析
  • 糖尿病足溃疡生技药品市场分析工具
    • 产业分析—波特五力分析
    • PESTEL分析

第四章糖尿病足溃疡生技药品市场：产品评估与趋势分析

  • 细分仪表板
  • 全球糖尿病足溃疡生技药品市场的波动
  • 全球糖尿病足溃疡生技药品市场规模及趋势分析（按产品划分）（2018-2030）
    • 皮肤替代品
    • 生长因子
    • 组织工程产品

第五章糖尿病足溃疡生技药品市场：适应症预测及趋势分析

  • 细分仪表板
  • 全球糖尿病足溃疡生技药品市场的波动
  • 2018-2030年全球糖尿病足溃疡生技药品市场规模及趋势分析（依适应症）
    • 神经缺血性溃疡
    • 神经病变糖尿病足溃疡
    • 缺血性糖尿病足溃疡

6. 糖尿病足溃疡生技药品市场：最终用途估计与趋势分析

  • 细分仪表板
  • 全球糖尿病足溃疡生技药品市场的波动
  • 2018-2030年全球糖尿病足溃疡生技药品市场规模及趋势分析（依最终用途）
  • 医院
  • 诊所
  • 门诊手术中心（ASC）
  • 长期照护机构
  • 其他的

7. 糖尿病足溃疡生技药品市场（按地区）、预测与趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测与趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 印度
    • 中国
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章竞争格局

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • 2024年主要企业市场占有率分析
    • Organogenesis Holdings Inc.
    • Tissue Regenix
    • BioTissue
    • Integra LifeSciences
    • MIMEDX Group, Inc.
    • Convatec Inc.
    • Coloplast Group（Kerecis）
    • Biocomposites
    • Smith+Nephew, Inc.
    • Stedical Scientific, Inc.
    • Zimmer Biomet
    • GUNZE LIMITED
  • 热图分析/企业市场分析
  • 2024年企业市场占有率预测分析
  • 其他主要市场参与企业
Product Code: GVR-4-68040-543-1

Diabetic Foot Ulcer Biologics Market Growth & Trends:

The global diabetic foot ulcer biologics market size is anticipated to reach USD 3.11 billion by 2030 and is projected to grow at a CAGR of 7.9% from 2025 to 2030, based on a new report by Grand View Research, Inc. This growth can be attributed to the growing competition among the market participants, rising research activities, the increasing number of clinical trials and studies along with increasing geriatric population. Moreover, the rising focus of industry players on expanding their presence is anticipated to propel market growth in the coming years.

For instance, a study from the National Library of Medicine in August 2022 reported that the risk of DFU increases with age. This correlation is closely linked to the longer duration of diabetes, the cumulative effects of hyperglycemia, and a higher prevalence of micro- and macrovascular complications. Therefore, the increasing prevalence of the geriatric population is expected to lead to a rise in diabetic foot ulcers. According to data published by the WHO in October 2024, the number of older people is estimated to increase significantly in the coming years. Below are some projections given by the WHO:

  • By 2030, 1 in 6 people worldwide will be aged 60 or older, with the population in this age group growing from 1 billion in 2020 to 1.4 billion.
  • By 2050, the worldwide population of individuals aged 60 and above is estimated to double, reaching 2.1 billion.
  • The number of people aged 80 or older is expected to triple from 2020 to 2050, reaching 426 million.

The increasing number of clinical trials is also expected to drive the market during the forecast period, attracting several companies to develop innovative treatments for diabetic foot ulcers. Various industry participants are actively engaged in clinical studies to bring novel biologics in the industry. For instance, in January 2025, RION, a clinical-stage regenerative medicine company, announced the completion of patient enrollment for its Phase 2 clinical trial of the Purified Exosome Product (PEP) in treating diabetic foot ulcers (DFUs). This prospective, multicenter, open-label study enrolled 59 patients across the U.S. It aims to assess the safety and efficacy of PEP when applied topically alongside standard wound care. PEP is a proprietary, lyophilized powder derived from human platelets that contains stabilized regenerative exosomes. These exosomes are engineered to enhance the body's natural healing processes by promoting cellular growth and reducing inflammation while also protecting vulnerable tissues-crucial elements for successful wound healing.

Diabetic Foot Ulcer Biologics Market Report Highlights:

  • Based on product, the skin substitutes segment dominated the global diabetic foot ulcer biologics market in 2024. On the other hand, the tissue-engineered products segment is anticipated to grow at the fastest in the coming years.
  • Based on indication, the neuro-ischemic ulcers segment held the largest revenue share of around 53.17% in the market in 2024. In contrast, the ischemic diabetic foot ulcer segment is expected to grow the fastest CAGR over the forecast period.
  • Based on end use, the hospital segment dominated the market and accounted for a revenue share of 51.52% in 2024. On the other hand, ambulatory surgical centers segment is expected to grow the fastest over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Third Party Perspective
    • 1.3.5. Primary research
    • 1.3.6. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Data Sources
  • 1.8. List of Primary Sources
  • 1.9. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Diabetic Foot Ulcer Biologics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of diabetic foot ulcer
      • 3.2.1.2. Technological advancements in biologics
      • 3.2.1.3. Rising geriatric population
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of biologics products
    • 3.2.3. Market opportunity analysis
      • 3.2.3.1. Rising distribution agreement for biologics
      • 3.2.3.2. Growing number of clinical trials
      • 3.2.3.3. Expansion of manufacturing and distribution facilities
      • 3.2.3.4. Expansion in emerging markets
    • 3.2.4. Market challenge analysis
      • 3.2.4.1. Intense Competition
  • 3.3. Diabetic Foot Ulcer Biologics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal Landscape
      • 3.3.2.2. Economic and Social Landscape
      • 3.3.2.3. Technological landscape

Chapter 4. Diabetic Foot Ulcer Biologics Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Diabetic Foot Ulcer Biologics Market Movement Analysis
  • 4.3. Global Diabetic Foot Ulcer Biologics Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
    • 4.3.1. Skin Substitutes
      • 4.3.1.1. Skin-Substitutes market estimates and forecast 2018 to 2030 (USD Million)
      • 4.3.1.2. Biological
        • 4.3.1.2.1. Biological market estimates and forecast 2018 to 2030 (USD Million)
      • 4.3.1.3. Synthetic
        • 4.3.1.3.1. Synthetic market estimates and forecast 2018 to 2030 (USD Million)
      • 4.3.1.4. Bio-Synthetic
        • 4.3.1.4.1. Bio-Synthetic market estimates and forecast 2018 to 2030 (USD Million)
    • 4.3.2. Growth Factors
      • 4.3.2.1. Growth factors market estimates and forecast 2018 to 2030 (USD Million)
    • 4.3.3. Tissue-Engineered Products
      • 4.3.3.1. Tissue-engineered products market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Diabetic Foot Ulcer Biologics Market: Indication Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Diabetic Foot Ulcer Biologics Market Movement Analysis
  • 5.3. Global Diabetic Foot Ulcer Biologics Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
    • 5.3.1. Neuro-ischemic Ulcers
      • 5.3.1.1. Neuro-ischemic ulcers market estimates and forecast 2018 to 2030 (USD Million)
    • 5.3.2. Neuropathic Diabetic Foot Ulcer
      • 5.3.2.1. Neuropathic diabetic foot ulcer market estimates and forecast 2018 to 2030 (USD Million)
    • 5.3.3. Ischemic Diabetic Foot Ulcer
      • 5.3.3.1. Ischemic diabetic foot ulcer market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Diabetic Foot Ulcer Biologics Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Diabetic Foot Ulcer Biologics Market Movement Analysis
  • 6.3. Global Diabetic Foot Ulcer Biologics Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Hospitals market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5. Clinics
    • 6.5.1. Clinics market estimates and forecast 2018 to 2030 (USD Million)
  • 6.6. Ambulatory Surgical Centers (ASCs)
    • 6.6.1. Ambulatory Surgical Centers (ASCs) market estimates and forecast 2018 to 2030 (USD Million)
  • 6.7. Long-Term Care Settings
    • 6.7.1. Long-term care settings market estimates and forecast 2018 to 2030 (USD Million)
  • 6.8. Others
    • 6.8.1. Others market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Diabetic Foot Ulcer Biologics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
  • 7.3. North America
    • 7.3.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Competitive scenario
      • 7.3.2.3. Regulatory framework
      • 7.3.2.4. Reimbursement scenario
      • 7.3.2.5. U.S. market estimates and forecasts, 2018 - 2030
    • 7.3.3. Canada
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Competitive scenario
      • 7.3.3.3. Regulatory framework
      • 7.3.3.4. Reimbursement scenario
      • 7.3.3.5. Canada market estimates and forecasts, 2018 - 2030
    • 7.3.4. Mexico
      • 7.3.4.1. Key country dynamics
      • 7.3.4.2. Competitive scenario
      • 7.3.4.3. Regulatory framework
      • 7.3.4.4. Reimbursement scenario
      • 7.3.4.5. Mexico market estimates and forecasts, 2018 - 2030
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Competitive scenario
      • 7.4.1.3. Regulatory framework
      • 7.4.1.4. Reimbursement scenario
      • 7.4.1.5. UK market estimates and forecasts, 2018 - 2030
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. Reimbursement scenario
      • 7.4.2.5. Germany market estimates and forecasts, 2018 - 2030
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Reimbursement scenario
      • 7.4.3.5. France market estimates and forecasts, 2018 - 2030
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Competitive scenario
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. Reimbursement scenario
      • 7.4.4.5. Italy market estimates and forecasts, 2018 - 2030
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Competitive scenario
      • 7.4.5.3. Regulatory framework
      • 7.4.5.4. Reimbursement scenario
      • 7.4.5.5. Spain market estimates and forecasts, 2018 - 2030
    • 7.4.6. Denmark
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Competitive scenario
      • 7.4.6.3. Regulatory framework
      • 7.4.6.4. Reimbursement scenario
      • 7.4.6.5. Denmark market estimates and forecasts, 2018 - 2030
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Competitive scenario
      • 7.4.7.3. Regulatory framework
      • 7.4.7.4. Reimbursement scenario
      • 7.4.7.5. Sweden market estimates and forecasts, 2018 - 2030
    • 7.4.8. Norway
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Competitive scenario
      • 7.4.8.3. Regulatory framework
      • 7.4.8.4. Reimbursement scenario
      • 7.4.8.5. Norway market estimates and forecasts, 2018 - 2030
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Competitive scenario
      • 7.5.1.3. Regulatory framework
      • 7.5.1.4. Reimbursement scenario
      • 7.5.1.5. Japan market estimates and forecasts, 2018 - 2030
    • 7.5.2. India
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Reimbursement scenario
      • 7.5.2.5. India market estimates and forecasts, 2018 - 2030
    • 7.5.3. China
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. Reimbursement scenario
      • 7.5.3.5. China market estimates and forecasts, 2018 - 2030
    • 7.5.4. South Korea
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. Reimbursement scenario
      • 7.5.4.5. South Korea market estimates and forecasts, 2018 - 2030
    • 7.5.5. Australia
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Reimbursement scenario
      • 7.5.5.5. Australia market estimates and forecasts, 2018 - 2030
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. Reimbursement scenario
      • 7.5.6.5. Thailand market estimates and forecasts, 2018 - 2030
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Competitive scenario
      • 7.6.1.3. Regulatory framework
      • 7.6.1.4. Reimbursement scenario
      • 7.6.1.5. Brazil market estimates and forecasts, 2018 - 2030
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Reimbursement scenario
      • 7.6.2.5. Argentina market estimates and forecasts, 2018 - 2030
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Competitive scenario
      • 7.7.1.3. Regulatory framework
      • 7.7.1.4. Reimbursement scenario
      • 7.7.1.5. South Africa market estimates and forecasts, 2018 - 2030
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Reimbursement scenario
      • 7.7.2.5. Saudi Arabia market estimates and forecasts, 2018 - 2030
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Reimbursement scenario
      • 7.7.3.5. UAE market estimates and forecasts, 2018 - 2030
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Competitive scenario
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. Reimbursement scenario
      • 7.7.4.5. Kuwait market estimates and forecasts, 2018 - 2030

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Organogenesis Holdings Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Tissue Regenix
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. BioTissue
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Integra LifeSciences
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. MIMEDX Group, Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Convatec Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Coloplast Group (Kerecis)
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Biocomposites
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Smith+Nephew, Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Stedical Scientific, Inc.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. Zimmer Biomet
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Product benchmarking
      • 8.3.14.4. Strategic initiatives
    • 8.3.15. GUNZE LIMITED
      • 8.3.15.1. Company overview
      • 8.3.15.2. Financial performance
      • 8.3.15.3. Product benchmarking
      • 8.3.15.4. Strategic initiatives
  • 8.4. Heat Map Analysis/ Company Market Position Analysis
  • 8.5. Estimated Company Market Share Analysis, 2024
  • 8.6. List of Other Key Market Players

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviation
  • Table 3. North America diabetic foot ulcer biologics market, by country, 2018 - 2030 (USD Million)
  • Table 4. North America diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 5. North America diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 6. North America diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 7. U.S. diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 8. U.S. diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 9. U.S. diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 10. Canada diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 11. Canada diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 12. Canada diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 13. Mexico diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 14. Mexico diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 15. Mexico diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 16. Europe diabetic foot ulcer biologics market, by country, 2018 - 2030 (USD Million)
  • Table 17. Europe diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 18. Europe diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 19. Europe diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 20. UK diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 21. UK diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 22. UK diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 23. Germany diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 24. Germany diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 25. Germany diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 26. France diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 27. France diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 28. France diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 29. Italy diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 30. Italy diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 31. Italy diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 32. Spain diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 33. Spain diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 34. Spain diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 35. Denmark diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 36. Denmark diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 37. Denmark diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 38. Sweden diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 39. Sweden diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 40. Sweden diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 41. Norway diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 42. Norway diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 43. Norway diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 44. Asia Pacific diabetic foot ulcer biologics market, by country, 2018 - 2030 (USD Million)
  • Table 45. Asia Pacific diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 46. Asia Pacific diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 47. Asia Pacific diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 48. China diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 49. China diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 50. China diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 51. Japan diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 52. Japan diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 53. Japan diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 54. India diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 55. India diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 56. India diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 57. South Korea diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 58. South Korea diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 59. South Korea diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 60. Australia diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 61. Australia diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 62. Australia diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 63. Thailand diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 64. Thailand diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 65. Thailand diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 66. Latin America diabetic foot ulcer biologics market, by country, 2018 - 2030 (USD Million)
  • Table 67. Latin America diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 68. Latin America diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 69. Latin America diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 70. Brazil diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 71. Brazil diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 72. Brazil diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 73. Mexico diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 74. Mexico diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 75. Mexico diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 76. Argentina diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 77. Argentina diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 78. Argentina diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 79. Middle East & Africa diabetic foot ulcer biologics market, by country, 2018 - 2030 (USD Million)
  • Table 80. Middle East & Africa diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 81. Middle East & Africa diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 82. Middle East & Africa diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 83. South Africa diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 84. South Africa diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 85. South Africa diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 86. Saudi Arabia diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 87. Saudi Arabia diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 88. Saudi Arabia diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 89. UAE diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 90. UAE diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 91. UAE diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)
  • Table 92. Kuwait diabetic foot ulcer biologics market, by product, 2018 - 2030 (USD Million)
  • Table 93. Kuwait diabetic foot ulcer biologics market, by indication, 2018 - 2030 (USD Million)
  • Table 94. Kuwait diabetic foot ulcer biologics market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Diabetic Foot Ulcer Biologics Market, Market Segmentation
  • Fig. 7 Market Driver Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Analysis (Current & Future Impact)
  • Fig. 9 Market Opportunity Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Analysis (Current & Future Impact)
  • Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 12 Porter's Five Forces Analysis
  • Fig. 13 Regional Marketplace: Key Takeaways
  • Fig. 14 Global Diabetic Foot Ulcer Biologics Market, for Product, 2018 - 2030 (USD Million)
  • Fig. 15 Global Diabetic Foot Ulcer Biologics Market, for Skin Substitutes, 2018 - 2030 (USD Million)
  • Fig. 16 Global Diabetic Foot Ulcer Biologics Market, for Biological, 2018 - 2030 (USD Million)
  • Fig. 17 Global Diabetic Foot Ulcer Biologics Market, for Synthetic, 2018 - 2030 (USD Million)
  • Fig. 18 Global Diabetic Foot Ulcer Biologics Market, for Bio-Synthetic, 2018 - 2030 (USD Million)
  • Fig. 19 Global Diabetic Foot Ulcer Biologics Market, for Growth Factors, 2018 - 2030 (USD Million)
  • Fig. 20 Global Diabetic Foot Ulcer Biologics Market, for Tissue-Engineered Products, 2018 - 2030 (USD Million)
  • Fig. 21 Global Diabetic Foot Ulcer Biologics Market, for Indication, 2018 - 2030 (USD Million)
  • Fig. 22 Global Diabetic Foot Ulcer Biologics Market, for Neuro-ischemic Ulcers, 2018 - 2030 (USD Million)
  • Fig. 23 Global Diabetic Foot Ulcer Biologics Market, for Neuropathic Diabetic Foot Ulcer, 2018 - 2030 (USD Million)
  • Fig. 24 Global Diabetic Foot Ulcer Biologics Market, for Ischemic Diabetic Foot Ulcer, 2018 - 2030 (USD Million)
  • Fig. 25 Global Diabetic Foot Ulcer Biologics Market, for End Use, 2018 - 2030 (USD Million)
  • Fig. 26 Global Diabetic Foot Ulcer Biologics Market, for Hospitals, 2018 - 2030 (USD Million)
  • Fig. 27 Global Diabetic Foot Ulcer Biologics Market, for Clinics, 2018 - 2030 (USD Million)
  • Fig. 28 Global Diabetic Foot Ulcer Biologics Market, for Ambulatory Surgical Centers (ASCs), 2018 - 2030 (USD Million)
  • Fig. 29 Global Diabetic Foot Ulcer Biologics Market, for Long-Term Care Settings, 2018 - 2030 (USD Million)
  • Fig. 30 Global Diabetic Foot Ulcer Biologics Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 31 Regional Outlook, 2024 & 2030
  • Fig. 32 North America Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 34 Canada Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 35 Mexico Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 36 Europe Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 38 UK Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 39 France Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 40 Italy Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 41 Spain Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 42 Denmark Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 43 Sweden Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 44 Norway Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 45 Asia Pacific Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 46 Japan Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 47 China Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 48 India Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 49 Australia Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 50 South Korea Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 51 Thailand Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 52 Latin America Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 53 Brazil Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 54 Argentina Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 55 Middle East and Africa Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 56 South Africa Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 57 Saudi Arabia Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 58 UAE Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 59 Kuwait Diabetic Foot Ulcer Biologics Market, 2018 - 2030 (USD Million)